<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00876993</url>
  </required_header>
  <id_info>
    <org_study_id>ACH-CNS-001</org_study_id>
    <nct_id>NCT00876993</nct_id>
  </id_info>
  <brief_title>Study of Irinotecan and Bevacizumab With Temozolomide in Refractory/Relapsed Central Nervous System (CNS) Tumors</brief_title>
  <official_title>A Phase I Study Of Irinotecan and Bevacizumab With Temozolomide in Children With Recurrent/Refractory Central Nervous System Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Johns Hopkins All Children's Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>V Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Brain Tumor Alliance</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Johns Hopkins All Children's Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Bevacizumab, irinotecan, and temozolomide are three agents shown to have promising activity
      in a variety of central nervous system tumors. No prospective studies have been published or
      are currently in progress within the major consortiums with this combination of drugs. Brain
      tumors are the second most common cause of cancer in pediatrics and the leading cause of
      cancer death in children. For children with High Grade Gliomas or with relapsed/refractory
      brain tumors, new agents in new combinations are needed. Historical data shows that newly
      diagnosed high grade gliomas 5 year progression free survival is 28-42%. Recurrent malignant
      gliomas median survival is 3-9 months. Recurrent medulloblastoma's 2 years survival is 9%.
      This study is a phase I study designed to provide an objective observation of toxicity and
      establish a maximum tolerated dose of this combination. In addition, this study will observe
      the response of children with relapsed or refractory central nervous system tumors.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Bevacizumab dosing is 10 mg/kg on day 1 and day 15 of a 28 days course given IV.

      Irinotecan dosing is 125 mg/m2 on day 1 and day 15 of a 28 day course given IV for the first
      3 dose levels. If the MTD of temozolomide is not reached at dose level 3, then dose level 4
      will be an escalation of irinotecan to 150 mg/m2.

      For dose level 0 Temozolomide, dosing is 75 mg/m2/day day 1-5 of a 28 day course given PO.
      Doses will be escalated according to standard phase I dose escalation criteria.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2008</start_date>
  <completion_date type="Actual">September 2015</completion_date>
  <primary_completion_date type="Actual">September 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Measurement of Number of Adverse Events</measure>
    <time_frame>Two 28-day cycles</time_frame>
    <description>Collect and grade the all of the adverse events to evaluate for safety. This data was collected for the first 2 cycles for each participant.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Best Response of Children With Recurrent or Refractory Central Nervous System Tumors With This Combination of Chemotherapy Agents.</measure>
    <time_frame>Every 2 cycles up to 24 cycles</time_frame>
    <description>Best response by MRIs per definitions in the protocol (complete response, partial response, stable disease, progressive disease). MRI's were obtained every 2 cycles and the best response was reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>2 Year Event Free Survival With Children Treated With This Regimen.</measure>
    <time_frame>2 year</time_frame>
    <description>2 year actual event free survival.with children treated with this protocol</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To Provide Safety and Efficacy Data for to Recommend Further Larger Studies.</measure>
    <time_frame>Two 28 day cycles</time_frame>
    <description>Number participants with grade 3 and 4 hematologic and non-hematologic toxicities. All toxicities are for end of cycle 2.</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">26</enrollment>
  <condition>Central Nervous System Tumors</condition>
  <arm_group>
    <arm_group_label>Dose Level 0</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Bevacizmuab 10 mg/kg IV Irinotecan 125 mg/m^2 IV Temozolomide 75 mg/m^2 PO</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose Level 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Bevacizmuab 10 mg/kg IV Irinotecan 125 mg/m^2 IV Temozolomide 125 mg/m^2 PO</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose Level 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Bevacizmuab 10 mg/kg IV Irinotecan 125 mg/m^2 IV Temozolomide 175 mg/m^2 PO</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose Level 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Bevacizmuab 10 mg/kg IV Irinotecan 125 mg/m^2 IV Temozolomide 200 mg/m^2 PO</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose Level 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Bevacizmuab 10 mg/kg IV Irinotecan 150 mg/m^2 IV Temozolomide 200 mg/m^2 PO</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bevacizumab</intervention_name>
    <description>Bevacizumab 10 mg/kg IV on day 1 and day 15 of a 28 day cycle</description>
    <arm_group_label>Dose Level 0</arm_group_label>
    <arm_group_label>Dose Level 1</arm_group_label>
    <arm_group_label>Dose Level 2</arm_group_label>
    <arm_group_label>Dose Level 3</arm_group_label>
    <arm_group_label>Dose Level 4</arm_group_label>
    <other_name>Irinotecan and temozolomide</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Irinotecan</intervention_name>
    <description>Irinotecan 125 mg/m2 on day 1 and day 15 of a 28 day course given IV for the first 3 dose levels. If the Maximum Tolerated Dose of temozolomide is not reached at dose level 3, then dose level 4 will be an escalation of irinotecan to 150mg/m2.</description>
    <arm_group_label>Dose Level 0</arm_group_label>
    <arm_group_label>Dose Level 1</arm_group_label>
    <arm_group_label>Dose Level 2</arm_group_label>
    <arm_group_label>Dose Level 3</arm_group_label>
    <arm_group_label>Dose Level 4</arm_group_label>
    <other_name>Bevacizumab and temozolomide</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Temozolomide</intervention_name>
    <description>For the first cohort (dose level 0) of patients, dosing is 75 mg/m2/day day 1-5 of a 28 day course given PO for the first course. Doses will be escalated according to standard phase I dose escalation criteria. Dose levels are as follows (Dose level 1 = 125mg/m2, Dose level 2 = 175mg/m2, Dose levels 3 and 4 = 200 mg/m2)</description>
    <arm_group_label>Dose Level 0</arm_group_label>
    <arm_group_label>Dose Level 1</arm_group_label>
    <arm_group_label>Dose Level 2</arm_group_label>
    <arm_group_label>Dose Level 3</arm_group_label>
    <arm_group_label>Dose Level 4</arm_group_label>
    <other_name>Bevacizumab and irinotecan</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Medulloblastomas, high-grade glioma, low-grade glioma, and ependymoma are eligible.
             Other central nervous system tumors may be considered for treatment at discretion of
             investigator. Pathology is required unless diffuse intrinsic pontine glioma or optic
             pathway tumor.

          -  The patient should have failed first line therapy and be considered refractory,
             relapsed, or recurrent. Exceptions are high grade gliomas including brain stem
             gliomas.

          -  Age 18 months though age 23 years are eligible for this protocol.

          -  The patient may have received any of the agents, but not in this combination. Patients
             will not be eligible if they have received the combination of bevacizumab and IV
             irinotecan as prior therapy. They will not be eligible if they had progressive disease
             on any of these agents. Investigator discretion may also be used.

          -  Bone marrow should be recovered from prior therapy with ANC &gt;1500 and platelets
             &gt;100,000.

          -  Serum creatinine should be less than institutional upper limit of norm.

          -  ALT/AST &lt;3 times normal and bilirubin &lt;1.5 times normal.

          -  Neurologic symptoms should be stable for 1 week with stable or decreasing doses of
             steroids.

          -  Patients should not be pregnant or breast feeding.

        Exclusion Criteria:

          -  Patients with bleeding disorders or on anticoagulants.

          -  Uncontrolled hypertension.

          -  Other risks of bleeding determined on individual basis.

          -  Patients receiving enzyme inducing anticonvulsants.

          -  Patients with significant cardiac or pulmonary dysfunction that would compromise the
             patient's ability to tolerate protocol therapy or would likely interfere with the
             study procedures or results.

          -  For patients receiving bevacizumab, those who have had surgical procedures should not
             receive bevacizumab within 28 days of a major procedure, 14 days of an intermediate
             procedure and 7 days of a minor procedure. Lumbar punctures or placement of PICC lines
             are not considered minor procedures and may occur at any time prior to or during
             therapy.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Months</minimum_age>
    <maximum_age>23 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stacie Stapleton, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Johns Hopkins All Children's Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Johns Hopkins All Children's Hospital</name>
      <address>
        <city>Saint Petersburg</city>
        <state>Florida</state>
        <zip>33701</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>April 6, 2009</study_first_submitted>
  <study_first_submitted_qc>April 6, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 7, 2009</study_first_posted>
  <results_first_submitted>June 27, 2017</results_first_submitted>
  <results_first_submitted_qc>August 6, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">August 8, 2019</results_first_posted>
  <last_update_submitted>June 3, 2020</last_update_submitted>
  <last_update_submitted_qc>June 3, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 5, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Johns Hopkins All Children's Hospital</investigator_affiliation>
    <investigator_full_name>Stacie Stapleton, MD</investigator_full_name>
    <investigator_title>Director, Pediatric Neuro-Oncology Program</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nervous System Neoplasms</mesh_term>
    <mesh_term>Central Nervous System Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bevacizumab</mesh_term>
    <mesh_term>Irinotecan</mesh_term>
    <mesh_term>Temozolomide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>Will determine after further data analysis</ipd_description>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Cohort 1 - Dose Level 1</title>
          <description>Bevacizmuab 10 mg/kg IV days 1 and 15 Irinotecan 125 mg/m^2 IV days 1 and 15 Temozolomide 125 mg/m^2 PO days 1-5 28 day cycle</description>
        </group>
        <group group_id="P2">
          <title>Cohort 2 - Dose Level 0</title>
          <description>Bevacizmuab 10 mg/kg IV days 1 and 15 Irinotecan 125 mg/m^2 IV days 1 and 15 Temozolomide 75 mg/m^2 PO days 1-5 28 day cycle</description>
        </group>
        <group group_id="P3">
          <title>Cohort 3 - Dose Level 1</title>
          <description>Bevacizmuab 10 mg/kg IV days 1 and 15 Irinotecan 125 mg/m^2 IV days 1 and 15 Temozolomide 125 mg/m^2 PO days 1-5 28 day cycle</description>
        </group>
        <group group_id="P4">
          <title>Cohort 4 - Dose Level 2</title>
          <description>Bevacizmuab 10 mg/kg IV days 1 and 15 Irinotecan 125 mg/m^2 IV days 1 and 15 Temozolomide 175 mg/m^2 PO days 1-5 28 day cycle</description>
        </group>
        <group group_id="P5">
          <title>Cohort 5 - Dose Level 1</title>
          <description>Bevacizmuab 10 mg/kg IV days 1 and 15 Irinotecan 125 mg/m^2 IV days 1 and 15 Temozolomide 125 mg/m^2 PO days 1-5 28 day cycle</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="5"/>
                <participants group_id="P4" count="5"/>
                <participants group_id="P5" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="5"/>
                <participants group_id="P5" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Cohort 1 - Dose Level 1</title>
          <description>Bevacizmuab 10 mg/kg IV days 1 and 15 Irinotecan 125 mg/m^2 IV days 1 and 15 Temozolomide 125 mg/m^2 PO days 1-5 28 day cycle</description>
        </group>
        <group group_id="B2">
          <title>Cohort 2 - Dose Level 0</title>
          <description>Bevacizmuab 10 mg/kg IV days 1 and 15 Irinotecan 125 mg/m^2 IV days 1 and 15 Temozolomide 75 mg/m^2 PO days 1-5 28 day cycle</description>
        </group>
        <group group_id="B3">
          <title>Cohort 3 - Dose Level 1</title>
          <description>Bevacizmuab 10 mg/kg IV days 1 and 15 Irinotecan 125 mg/m^2 IV days 1 and 15 Temozolomide 125 mg/m^2 PO days 1-5 28 day cycle</description>
        </group>
        <group group_id="B4">
          <title>Cohort 4 - Dose Level 2</title>
          <description>Bevacizmuab 10 mg/kg IV days 1 and 15 Irinotecan 125 mg/m^2 IV days 1 and 15 Temozolomide 175 mg/m^2 PO days 1-5 28 day cycle</description>
        </group>
        <group group_id="B5">
          <title>Cohort 5 - Dose Level 1</title>
          <description>Bevacizmuab 10 mg/kg IV days 1 and 15 Irinotecan 125 mg/m^2 IV days 1 and 15 Temozolomide 125 mg/m^2 PO days 1-5 28 day cycle</description>
        </group>
        <group group_id="B6">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="5"/>
            <count group_id="B2" value="6"/>
            <count group_id="B3" value="5"/>
            <count group_id="B4" value="5"/>
            <count group_id="B5" value="5"/>
            <count group_id="B6" value="26"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9.2" lower_limit="5" upper_limit="14"/>
                    <measurement group_id="B2" value="8.5" lower_limit="2" upper_limit="18"/>
                    <measurement group_id="B3" value="11.4" lower_limit="4" upper_limit="22"/>
                    <measurement group_id="B4" value="9.8" lower_limit="3" upper_limit="17"/>
                    <measurement group_id="B5" value="10.6" lower_limit="6" upper_limit="14"/>
                    <measurement group_id="B6" value="9.8" lower_limit="2" upper_limit="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="5"/>
                    <measurement group_id="B6" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="3"/>
                    <measurement group_id="B6" value="13"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="2"/>
                    <measurement group_id="B6" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="3"/>
                    <measurement group_id="B6" value="16"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="5"/>
                    <measurement group_id="B5" value="5"/>
                    <measurement group_id="B6" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Diagnosis</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Medulloblastoma</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High Grade Glioma</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="2"/>
                    <measurement group_id="B6" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Low Grade Glioma</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Choroid Plexus Tumors</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ependymoma</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PNET</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Measurement of Number of Adverse Events</title>
        <description>Collect and grade the all of the adverse events to evaluate for safety. This data was collected for the first 2 cycles for each participant.</description>
        <time_frame>Two 28-day cycles</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1 - Dose Level 1</title>
            <description>Bevacizmuab 10 mg/kg IV days 1 and 15 Irinotecan 125 mg/m^2 IV days 1 and 15 Temozolomide 125 mg/m^2 PO days 1-5 28 day cycle</description>
          </group>
          <group group_id="O2">
            <title>Cohort 2 - Dose Level 0</title>
            <description>Bevacizmuab 10 mg/kg IV days 1 and 15 Irinotecan 125 mg/m^2 IV days 1 and 15 Temozolomide 75 mg/m^2 PO days 1-5 28 day cycle</description>
          </group>
          <group group_id="O3">
            <title>Cohort 3 - Dose Level 1</title>
            <description>Bevacizmuab 10 mg/kg IV days 1 and 15 Irinotecan 125 mg/m^2 IV days 1 and 15 Temozolomide 125 mg/m^2 PO days 1-5 28 day cycle</description>
          </group>
          <group group_id="O4">
            <title>Cohort 4 - Dose Level 2</title>
            <description>BBevacizmuab 10 mg/kg IV days 1 and 15 Irinotecan 125 mg/m^2 IV days 1 and 15 Temozolomide 175 mg/m^2 PO days 1-5 28 day cycle</description>
          </group>
          <group group_id="O5">
            <title>Cohort 5 - Dose Level 1</title>
            <description>Bevacizmuab 10 mg/kg IV days 1 and 15 Irinotecan 125 mg/m^2 IV days 1 and 15 Temozolomide 125 mg/m^2 PO days 1-5 28 day cycle</description>
          </group>
        </group_list>
        <measure>
          <title>Measurement of Number of Adverse Events</title>
          <description>Collect and grade the all of the adverse events to evaluate for safety. This data was collected for the first 2 cycles for each participant.</description>
          <units>Adverse events</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="3"/>
                <count group_id="O4" value="5"/>
                <count group_id="O5" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Grade 1 adverse events</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="5"/>
                    <measurement group_id="O5" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 2 adverse events</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="5"/>
                    <measurement group_id="O5" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 adverse events</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="4"/>
                    <measurement group_id="O5" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 4 adverse events</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Best Response of Children With Recurrent or Refractory Central Nervous System Tumors With This Combination of Chemotherapy Agents.</title>
        <description>Best response by MRIs per definitions in the protocol (complete response, partial response, stable disease, progressive disease). MRI's were obtained every 2 cycles and the best response was reported.</description>
        <time_frame>Every 2 cycles up to 24 cycles</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1 - Dose Level 1</title>
            <description>Bevacizmuab 10 mg/kg IV days 1 and 15 Irinotecan 125 mg/m^2 IV days 1 and 15 Temozolomide 125 mg/m^2 PO days 1-5 28 day cycle</description>
          </group>
          <group group_id="O2">
            <title>Cohort 2 - Dose Level 0</title>
            <description>Bevacizmuab 10 mg/kg IV days 1 and 15 Irinotecan 125 mg/m^2 IV days 1 and 15 Temozolomide 75 mg/m^2 PO days 1-5 28 day cycle</description>
          </group>
          <group group_id="O3">
            <title>Cohort 3 - Dose Level 1</title>
            <description>Bevacizmuab 10 mg/kg IV days 1 and 15 Irinotecan 125 mg/m^2 IV days 1 and 15 Temozolomide 125 mg/m^2 PO days 1-5 28 day cycle</description>
          </group>
          <group group_id="O4">
            <title>Cohort 4 - Dose Level 2</title>
            <description>Bevacizmuab 10 mg/kg IV days 1 and 15 Irinotecan 125 mg/m^2 IV days 1 and 15 Temozolomide 175 mg/m^2 PO days 1-5 28 day cycle</description>
          </group>
          <group group_id="O5">
            <title>Cohort 5 - Dose Level 1</title>
            <description>Bevacizmuab 10 mg/kg IV days 1 and 15 Irinotecan 125 mg/m^2 IV days 1 and 15 Temozolomide 125 mg/m^2 PO days 1-5 28 day cycle</description>
          </group>
        </group_list>
        <measure>
          <title>Best Response of Children With Recurrent or Refractory Central Nervous System Tumors With This Combination of Chemotherapy Agents.</title>
          <description>Best response by MRIs per definitions in the protocol (complete response, partial response, stable disease, progressive disease). MRI's were obtained every 2 cycles and the best response was reported.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="3"/>
                <count group_id="O4" value="5"/>
                <count group_id="O5" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Complete Response</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Partial Response</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="3"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Stable Disease</title>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Progressive Disease</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>2 Year Event Free Survival With Children Treated With This Regimen.</title>
        <description>2 year actual event free survival.with children treated with this protocol</description>
        <time_frame>2 year</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1 - Dose Level 1</title>
            <description>Bevacizmuab 10 mg/kg IV days 1 and 15 Irinotecan 125 mg/m^2 IV days 1 and 15 Temozolomide 125 mg/m^2 PO days 1-5 28 day cycle</description>
          </group>
          <group group_id="O2">
            <title>Cohort 2 - Dose Level 0</title>
            <description>Bevacizmuab 10 mg/kg IV days 1 and 15 Irinotecan 125 mg/m^2 IV days 1 and 15 Temozolomide 75 mg/m^2 PO days 1-5 28 day cycle</description>
          </group>
          <group group_id="O3">
            <title>Cohort 3 - Dose Level 1</title>
            <description>Bevacizmuab 10 mg/kg IV days 1 and 15 Irinotecan 125 mg/m^2 IV days 1 and 15 Temozolomide 125 mg/m^2 PO days 1-5 28 day cycle</description>
          </group>
          <group group_id="O4">
            <title>Cohort 4 - Dose Level 2</title>
            <description>Bevacizmuab 10 mg/kg IV days 1 and 15 Irinotecan 125 mg/m^2 IV days 1 and 15 Temozolomide 175 mg/m^2 PO days 1-5 28 day cycle</description>
          </group>
          <group group_id="O5">
            <title>Cohort 5 - Dose Level 1</title>
            <description>Bevacizmuab 10 mg/kg IV days 1 and 15 Irinotecan 125 mg/m^2 IV days 1 and 15 Temozolomide 125 mg/m^2 PO days 1-5 28 day cycle</description>
          </group>
        </group_list>
        <measure>
          <title>2 Year Event Free Survival With Children Treated With This Regimen.</title>
          <description>2 year actual event free survival.with children treated with this protocol</description>
          <units>Count of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="3"/>
                <count group_id="O4" value="5"/>
                <count group_id="O5" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="5"/>
                    <measurement group_id="O5" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>To Provide Safety and Efficacy Data for to Recommend Further Larger Studies.</title>
        <description>Number participants with grade 3 and 4 hematologic and non-hematologic toxicities. All toxicities are for end of cycle 2.</description>
        <time_frame>Two 28 day cycles</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1 - Dose Level 1</title>
            <description>Bevacizmuab 10 mg/kg IV days 1 and 15 Irinotecan 125 mg/m^2 IV days 1 and 15 Temozolomide 125 mg/m^2 PO days 1-5 28 day cycle</description>
          </group>
          <group group_id="O2">
            <title>Cohort 2 - Dose Level 0</title>
            <description>Bevacizmuab 10 mg/kg IV days 1 and 15 Irinotecan 125 mg/m^2 IV days 1 and 15 Temozolomide 75 mg/m^2 PO days 1-5 28 day cycle</description>
          </group>
          <group group_id="O3">
            <title>Cohort 3 - Dose Level 1</title>
            <description>Bevacizmuab 10 mg/kg IV days 1 and 15 Irinotecan 125 mg/m^2 IV days 1 and 15 Temozolomide 125 mg/m^2 PO days 1-5 28 day cycle</description>
          </group>
          <group group_id="O4">
            <title>Cohort 4 - Dose Level 2</title>
            <description>Bevacizmuab 10 mg/kg IV days 1 and 15 Irinotecan 125 mg/m^2 IV days 1 and 15 Temozolomide 175 mg/m^2 PO days 1-5 28 day cycle</description>
          </group>
          <group group_id="O5">
            <title>Cohort 5 - Dose Level 1</title>
            <description>BBevacizmuab 10 mg/kg IV days 1 and 15 Irinotecan 125 mg/m^2 IV days 1 and 15 Temozolomide 125 mg/m^2 PO days 1-5 28 day cycle</description>
          </group>
        </group_list>
        <measure>
          <title>To Provide Safety and Efficacy Data for to Recommend Further Larger Studies.</title>
          <description>Number participants with grade 3 and 4 hematologic and non-hematologic toxicities. All toxicities are for end of cycle 2.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="3"/>
                <count group_id="O4" value="5"/>
                <count group_id="O5" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Grade 3 &amp; 4 Blood/Bone Marrow</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 &amp; 4 Gastrointestinal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 &amp; 4 Metabolic/Laboratory</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 &amp; 4 Musculoskelatal/Soft Tissue</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 &amp; 4 Neurology</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="3"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 &amp; 4 Pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 &amp; 4 Vascular</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 &amp; 4 Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Two 28 day cycles for each participant</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Cohort 1 - Dose Level 1</title>
          <description>Bevacizmuab 10 mg/kg IV days 1 and 15 Irinotecan 125 mg/m^2 IV days 1 and 15 Temozolomide 125 mg/m^2 PO days 1-5 28 day cycle</description>
        </group>
        <group group_id="E2">
          <title>Cohort 2 - Dose Level 0</title>
          <description>Bevacizmuab 10 mg/kg IV days 1 and 15 Irinotecan 125 mg/m^2 IV days 1 and 15 Temozolomide 75 mg/m^2 PO days 1-5 28 day cycle</description>
        </group>
        <group group_id="E3">
          <title>Cohort 3 - Dose Level 1</title>
          <description>Bevacizmuab 10 mg/kg IV days 1 and 15 Irinotecan 125 mg/m^2 IV days 1 and 15 Temozolomide 125 mg/m^2 PO days 1-5 28 day cycle</description>
        </group>
        <group group_id="E4">
          <title>Cohort 4 - Dose Level 2</title>
          <description>Bevacizmuab 10 mg/kg IV days 1 and 15 Irinotecan 125 mg/m^2 IV days 1 and 15 Temozolomide 175 mg/m^2 PO days 1-5 28 day cycle</description>
        </group>
        <group group_id="E5">
          <title>Cohort 5 - Dose Level 1</title>
          <description>Bevacizmuab 10 mg/kg IV days 1 and 15 Irinotecan 125 mg/m^2 IV days 1 and 15 Temozolomide 125 mg/m^2 PO days 1-5 28 day cycle</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Hemolytic anemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>GI illness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="5"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Neurology, other - pneumocephalus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Neurologic deficits</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Shunt malfunction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="5"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Dystonic reaction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Thrombus - embolism</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="5"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Leukocytes</sub_title>
                <description>Grade 3 and 4</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Neutrophils</sub_title>
                <description>Grade 3 and 4</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Lymphocytes</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Thrombus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>ALT/AST</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="5"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Syncope/Seizure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="5"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Stacie Stapleton</name_or_title>
      <organization>Johns Hopkins All Children's Hospital</organization>
      <phone>727-767-4176</phone>
      <email>stacie.stapleton@jhmi.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

